Deep and Durable Responses with Weekly Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Follow-up of Patients Not Undergoing Stem Cell Transplantation (SCT)

Triplet combinations including a proteasome inhibitor (PI) have been proven superior to doublets in NDMM. The only PI currently approved for use in NDMM is injectable bortezomib.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Shaji Kumar, Jesus Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob Laubach, Mehdi Hamadani, A. Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan Kaufman, Deborah Berg, Eileen Liao, Vincent Rajkumar, Paul Richardson Source Type: research